[HTML][HTML] ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
P Tarantino, G Viale, MF Press, X Hu… - Annals of …, 2023 - Elsevier
Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged
as a targetable subset of breast tumors, based on the evidence from clinical trials of novel …
as a targetable subset of breast tumors, based on the evidence from clinical trials of novel …
Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis
Background The prognostic differences between HER2-zero and HER2-low breast cancer
(BC) remain unclear. Purpose of this meta-analysis is to investigate the differences between …
(BC) remain unclear. Purpose of this meta-analysis is to investigate the differences between …
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
P Tarantino, H Gupta, ME Hughes, J Files… - Nature …, 2023 - nature.com
The molecular underpinnings of HER2-low and HER2-0 (IHC 0) breast tumors remain poorly
defined. Using genomic findings from 1039 patients with HER2-negative metastatic breast …
defined. Using genomic findings from 1039 patients with HER2-negative metastatic breast …
A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression
C Boman, X Liu, L Eriksson Bergman, W Sun… - British Journal of …, 2024 - nature.com
Background This study aimed to investigate the distribution and changes of HER2 status in
untreated tumours, in residual disease and in metastasis, and their long-term prognostic …
untreated tumours, in residual disease and in metastasis, and their long-term prognostic …
A gene expression-based classifier for HER2-low breast cancer
S Di Cosimo, S Pizzamiglio, CM Ciniselli, V Duroni… - Scientific Reports, 2024 - nature.com
In clinical trials evaluating antibody-conjugated drugs (ADCs), HER2-low breast cancer is
defined through protein immunohistochemistry scoring (IHC) 1+ or 2+ without gene …
defined through protein immunohistochemistry scoring (IHC) 1+ or 2+ without gene …
The impact of HER2-low status on pathological complete response and disease-free survival in early-stage breast cancer
Background The HER-2 status of breast cancer (BC) has been classified as negative or
positive for a long time. Given the efficacy of novel anti-HER2-targeted antibody drug …
positive for a long time. Given the efficacy of novel anti-HER2-targeted antibody drug …
HER2-low Breast Cancer: Now and in the Future
S Kang, SB Kim - Cancer Research and Treatment, 2024 - e-crt.org
Breast cancer is a heterogeneous disease, and its subtypes are characterized by hormone
receptor and human epidermal growth factor receptor 2 (HER2) expression status.“HER2 …
receptor and human epidermal growth factor receptor 2 (HER2) expression status.“HER2 …
[PDF][PDF] RESEARCH AND TREATMENT
WY Park, YC Ahn, DH Lee, HY Lee, EK Chie… - 2024 - e-crt.org
Cancer Research and Treatment is a peer-reviewed open access publication of the Korean
Cancer Association, Korean Society of Medical Oncology, and Korean Association for Lung …
Cancer Association, Korean Society of Medical Oncology, and Korean Association for Lung …